Bio Plus Co

Bio Plus Co Equity Turnover

The Equity Turnover of Bio Plus Co (099430.KQ) as of Oct 22, 2026 is 0.52. In the previous year, Equity Turnover was 0.50 — a change of 4.50% (higher).

Equity Turnover

0.52

YoY

4.50%

Last updated:

Equity Turnover of Bio Plus Co is 2025 0.52 . Equity Turnover of Bio Plus Co was 2024 0.50 . It decreases by 4.50% higher compared to the previous year.

The Bio Plus Co Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
1.50 KRW
Jan 1, 2019
0.95 KRW
Jan 1, 2020
0.85 KRW
Jan 1, 2021
0.48 KRW
Jan 1, 2022
0.50 KRW
Jan 1, 2023
0.51 KRW
Jan 1, 2024
0.50 KRW
Jan 1, 2025
0.52 KRW
The Bio Plus Co Equity Turnover history
YEAREquity TurnoverYoY
0.52+4.50%
0.50-2.24%
0.51+1.62%
0.50+5.32%
0.48-44.35%
0.85-10.42%
0.95-36.31%
1.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Equity Turnover of Bio Plus Co is 0.52 in 2025.

Equity Turnover of Bio Plus Co changed from 0.50 to 0.52, representing a 4.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio Plus Co

All Key Metrics — Bio Plus Co